Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Development and characterization of high affinity leptins and leptin antagonists.

Shpilman M, Niv-Spector L, Katz M, Varol C, Solomon G, Ayalon-Soffer M, Boder E, Halpern Z, Elinav E, Gertler A.

J Biol Chem. 2011 Feb 11;286(6):4429-42. doi: 10.1074/jbc.M110.196402. Epub 2010 Nov 30.

2.

A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2.

Izhak L, Wildbaum G, Zohar Y, Anunu R, Klapper L, Elkeles A, Seagal J, Yefenof E, Ayalon-Soffer M, Karin N.

J Immunol. 2009 Jul 1;183(1):732-9. doi: 10.4049/jimmunol.0802746. Epub 2009 Jun 17.

3.

A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.

Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I, Ayalon-Soffer M.

Clin Cancer Res. 2008 Jul 15;14(14):4612-21. doi: 10.1158/1078-0432.CCR-08-0108.

4.

Folding and self-assembly do not prevent ER retention and proteasomal degradation of asialoglycoprotein receptor H2a.

Ayalon-Soffer M, Kamhi-Nesher S, Lederkremer GZ.

FEBS Lett. 1999 Oct 22;460(1):112-6.

5.

Differential role of mannose and glucose trimming in the ER degradation of asialoglycoprotein receptor subunits.

Ayalon-Soffer M, Shenkman M, Lederkremer GZ.

J Cell Sci. 1999 Oct;112 ( Pt 19):3309-18.

Supplemental Content

Loading ...
Support Center